In recent years, with the surge in popularity of skincare efficacy, cosmetic ingredients and raw materials have garnered significant attention. Among them, the multifaceted benefits of recombinant collagen have captured consumers’ interest, making it a highly competitive ingredient in the era of efficacy skincare.
As the “scaffold” and “elasticity network” of the skin, recombinant collagen exhibits anti-wrinkle, repair, and other effects. According to Frost & Sullivan’s predictions, the market size of recombinant collagen cosmetics is expected to reach 81 billion yuan by 2026, potentially becoming the largest professional skincare ingredient.
Among the numerous recombinant collagen enterprises, Jland Biotech, founded in 2015, may not have a long history, but it has emerged as a leader in the industry with a comprehensive industrial layout covering recombinant collagen ingredients, OEM/ODM, and branding, achieving a closed-loop “Business+Consumer” end.
In December last year, the well-known sportswear brand Hongxing Erke ventured into the beauty industry, launching the beauty brands “DUOYING” and “Emputone,” with JLand Biotech as its OEM enterprise. It is understood that Polybio currently has over 300 global cooperative brands and factories, including Proya and OSM. In the fiercely competitive recombinant collagen arena, Polybio has undoubtedly forged a unique development path based on its strengths.
Leader in the full industry chain of recombinant collagen protein
According to publicly available information, Jland Biotech, established in 2015, was jointly founded by Aland Group, the world’s largest nutrition provider, Professor Yang Shulin’s team, the inventor of recombinant human collagen (RHC) technology, and Nanjing University of Science and Technology (NJUST).
From its inception, Jland Biotech has focused on the integrated research and development, production, and application of recombinant collagen protein. As the first domestic high-tech enterprise to use Pichia yeast for the synthesis of recombinant collagen protein, after years of accumulation, Jland Biotech has achieved a full industry chain layout based on recombinant functional proteins, including gene design, strain construction, industrial design, tonnage capacity amplification, downstream application research and development, downstream product safety, and efficacy testing. It is a leading company in the recombinant collagen protein industry with a full industry chain.
As the company continues to grow, Jland Biotech has frequently gained favor in the capital market. According to publicly available information, during the period from 2021 to 2023, Jland Biotech has successively completed three rounds of financing. In September of last year, Evonik Industries, the largest raw material supplier for L’Oréal, completed a Series B investment in Jland Biotech, marking the first investment in a recombinant collagen protein enterprise in China by the latter.
It is worth noting that in November of last year, Jland Biotech was successfully selected as a potential unicorn enterprise in Jiangsu Province for the year 2023, becoming the only recombinant collagen protein company to be selected. According to the selection criteria, the valuation of Jland Biotech is estimated to be between 100 million and 1 billion US dollars.
How did Jland Biotech stand out in the fierce competition? It is through years of dedicated effort that Jland Biotech has accumulated a strong industrial advantage in the recombinant collagen protein industry.
It is understood that Jland Biotech has become one of the world’s largest suppliers of recombinant collagen protein, producing 20 tons of high-purity powder raw materials of recombinant collagen protein annually, equivalent to 5000 tons of recombinant collagen protein solution. Meanwhile, with the support of its technological platform, Jland Biotech has developed various functional proteins including Type I, and Type III recombinant collagen protein, and recombinant fibronectin, and achieved large-scale production.
According to public reports, Jland Biotech has also reserved Type IV, Type V, and Type XVII recombinant collagen proteins, which are expected to be put into production successively in the next two years. The purity, content, and endotoxin levels of Jland Biotech’s recombinant collagen proteins are all at the forefront of the industry.
For example, Jland Biotech’s Type III recombinant collagen protein is single-molecule, high-purity, with endotoxin levels below 0.05 EU/mg. It exhibits good human affinity, easy absorption, and high safety, promoting cell migration and proliferation, and forming a collagen network structure in real-time, facilitating autologous collagen regeneration. Meanwhile, Jland Biotech’s Type I recombinant collagen protein is based on AI big data calculation and lean screening of amino acid basic sequences. It contains not only the tripeptide signal recognition site RGD sequence but also more integrin recognition sites such as GER and GEK to support its biological functions. It can promote bone differentiation and vascular generation and can be widely used in tissue repair and filling treatments for bone tissue regeneration and wound healing.
Additionally, as a leading company in the recombinant collagen protein industry, Jland Biotech actively participates in the drafting of industry standards and group standards. It is known that Jland Biotech is one of the drafting units of the Chinese pharmaceutical industry standard YY/T1849-2022 Recombinant Collagen and has participated in the formulation of standards such as T/ZGKSL 004-2023 Recombinant Collagen for Cosmetics and T/ZGKSL 005-2023 Quality Requirements and Assessment for Recombinant Collagen.
As of now, Jland Biotech has obtained over 40 invention patent applications, including 33 domestically authorized invention patents and 9 international invention patents. It is also the first domestic enterprise in China to obtain FDA certification and overseas INCI names for recombinant human collagen protein materials.
Over 300 Global Collaborative Brands and Factories
Years of dedicated efforts have endowed Jland Biotech with unparalleled advantages in research and the extension of the industrial chain. Beyond large-scale raw material production, Jland Biotech has also established its own brand and cosmetics OEM processing business, providing comprehensive services ranging from product planning, and formula development to large-scale production for clients.
In the field of cosmetics OEM processing, Jland Biotech is known for its main business lines of functional skincare OEM processing and brand operations. With a focus on proprietary recombinant collagen protein materials, it has launched innovative freeze-dried repair series, active glass series, fibronectin series, anti-wrinkle series, and other skincare OEM products.
Specifically, Jland Biotech’s advantages in cosmetics OEM processing are threefold:
Firstly, it possesses Class 100,000 and Class 10,000 cleanrooms, ensuring extremely high raw material purity with minimal impurities and 100% homogeneity. Secondly, according to publicly available information, Jland Biotech’s endotoxin content is less than 0.05 EU/mg, which is ten times lower than pharmaceutical grade (0.5 EU/mg), a rarity in the industry.
Thirdly, with unique insights into the cosmetics market and professional quality control, Jland Biotech has gained recognition from over 300 globally renowned brands, including Huaxi Biotechnology, FuErJia, Shanghai Jahwa, Hongxingerke, and Osmann. Its products are exported to more than 80 countries and regions in Europe, North America, East Asia, the Middle East, and Latin America.
In December of last year, Jland Biotech entered into a strategic cooperation on the upstream and downstream of the industry chain with Hongxingerke Investment Company’s brand, Medicompass. Both parties will jointly develop a variety of recombinant collagen protein products for different application fields, including Type III recombinant human collagen protein solution, patches, repair gels, and gynecological gels.
Providing end-to-end assurance
To meet the diversified market demands, Jland Biotech focuses on long-term strategies, devoting efforts to research and develop products and constructing differentiated services to build a competitive advantage, creating high-quality products that cater to the needs of Chinese skin.
Jland Biotech’s technical advantages in cosmetics OEM processing are evident. Firstly, all equipment is managed through MES and linked with ERP, enabling smart manufacturing and minimizing external intervention. Secondly, Jland Biotech possesses proprietary AI freeze-drying ball production lines. Additionally, the company employs purification water systems, pharmaceutical bottle washing machine equipment, and medical-grade 316L stainless steel pipelines to eliminate secondary pollution.
Simultaneously, Jland Biotech provides end-to-end assurance, including regulatory guidance, raw material verification, quality control, market support, and efficacy testing. Specifically, in terms of regulatory guidance, the company assists enterprises in completing registration and approval audits, provides services for product labels, formula, and promotional copy review, and offers compliance guidance based on technical review opinions from the Drug Regulatory Authority after registration. For raw material verification, the company conducts full-process verification through raw material quality testing, formula product testing, and finished product efficacy evaluation. Quality control follows medical device/pharmaceutical enterprise standards throughout the entire process. Additionally, in terms of market support, Jland Biotech offers brand research planning, packaging design and development, and product technical training.
Regarding product differentiation, according to a spokesperson from Jland Biotech, “For the sub-category of freeze-dried recombinant collagen products, Jland Biotech is the most advantageous OEM factory in China.” It is worth noting that Jland Biotech possesses exclusive global freeze-drying and fresh-locking technology, which maximizes the efficacy and activity of recombinant collagen protein, ensuring the release of maximum efficacy when the product is used, while deeply locking in the formula.
It’s worth mentioning that from March 10th to March 12th, at the upcoming 63rd China (Guangzhou) International Beauty Expo, Jland Biotech will showcase a wide range of core formula products including repair series, bioactive glass series, fibronectin series, anti-wrinkle series, and more at Booth G08A in Hall B2.1.
The Fibronectin Whitening Series products adhere to the principles of scientific cyclic skincare and gentle whitening while incorporating sustainable development principles into the product line. They ensure effective whitening while maintaining skin health. The Fibronectin Series meets the requirements of 16 green beauty ingredients, avoiding controversial additives such as preservatives, fragrances, alcohol, and pigments. Additionally, to minimize the side effects of “whitening,” Jland Biotech has incorporated soothing active ingredients into the development of this series to reduce irritation, achieving gentle and sustainable whitening.
The Bioactive Glass Series utilizes highly active recombinant collagen protein ingredients combined with high-tech natural substance bioactive glass, effectively addressing skin issues such as pigmentation and skin laxity. According to the introduction, Jland Biotech’s Repair Series products are considered essential for sensitive skin, providing both stability and emergency relief. Specifically, to achieve robust “stability,” the products incorporate ingredients such as Type III recombinant human collagen protein and ceramide, strengthening the stratum corneum, repairing the skin barrier, and stabilizing nerve function. To achieve “emergency relief,” the products contain ingredients like Centella Asiatica, trehalose, and dipotassium glycyrrhizinate, which alleviate skin irritation symptoms and reduce neurovascular hyperreactivity.
Over the years, Jland Biotech has been continuously deepening its product strength, innovation capability, scientific research strength, and brand influence, while expanding the entire industry chain upstream and downstream of recombinant collagen protein. It can be anticipated that, as a pioneer, with the emergence of a new ecological industry chain model in the recombinant collagen protein industry, Jland Biotech will not only empower the industry but also usher in a new chapter in the application of recombinant collagen.
